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Virulence of and deaths from Clostridium diffi cile–asso-
ciated disease (CDAD) are on the rise in the United States. 
The incidence of adult CDAD hospitalizations doubled from 
5.5 cases per 10,000 population in 2000 to 11.2 in 2005, 
and the CDAD-related age-adjusted case-fatality rate rose 
from 1.2% in 2000 to 2.2% in 2004.
Clostridium diffi cile–associated disease (CDAD) rep-resents a considerable public health hazard. In the 
United States, it is responsible for more deaths than all 
other intestinal infections combined (1). Incidence, hospi-
talizations, and deaths related to CDAD have been on the 
rise (1–3). Emergence of hypervirulent strains and in vitro 
resistance to third-generation cephalosporins and fl uoro-
quinolones have also been reported (4). In view of these 
phenomena, it is unclear whether the recently reported 
35%-per-year increase in CDAD-related deaths represents 
a rise in case-fatality rate or refl ects increasing incidence of 
hospitalizations with this disease (1). We hypothesized the 
latter to be at least partially the cause. Given that 80% of all 
CDAD-related deaths occur in acute-care hospitals (1), we 
conducted a population-based analysis of CDAD-related 
adult hospitalizations in the period 2000–2005.
The Study
We identifi ed CDAD-related hospitalizations for 2000–
2005 from the National Inpatient Sample data (5), available 
on the Healthcare Costs and Utilization Project Net website, 
administered by the Agency for Healthcare Research and 
Quality (6). The National Inpatient Sample is a stratifi ed 
20% sample of US community hospitals, and the data are 
weighted to provide national estimates (5). CDAD was iden-
tifi ed by the presence of the International Classifi cation of 
Diseases, 9th revision, Clinical Modifi cation (ICD-9-CM), 
diagnosis code 8.45 (intestinal infection with Clostridium 
diffi cile), and the numbers of discharges per year were age 
stratifi ed. We obtained censal and intercensal data (numeri-
cal and demographic characteristics of the US population 
from 2000 through 2005) from the US Census Bureau (7). 
On the basis of these data, we calculated age-specifi c hospi-
talization incidence rates and fi tted linear models, using the 
least-squares method, to describe this age-specifi c growth. 
Finally, using the population-based CDAD mortality num-
bers in the report by Redelings et al. (1), we computed case-
fatality rates for hospitalized CDAD patients for the 5-year 
period from 2000 through 2004.
The number of adults discharged from US hospitals 
with a CDAD diagnosis rose by nearly 160,000, from 
134,361 in 2000 to 291,303 in 2005 (Table) (6). This 117% 
rise in CDAD discharges over a 5-year period equates to 
an ≈23% average crude growth annually. As a benchmark, 
we examined the changes in overall hospital discharges and 
discharges with CDAD as the principal diagnosis over the 
same period. We found the overall hospitalizations rose 
≈1.3% annually (from 36,417,565 in 2000 to 39,163,834 in 
2005). Although the absolute change in volume of cases for 
which CDAD was the principal diagnosis mirrored those in 
all CDAD admissions, the relative contribution of CDAD 
primary diagnosis to all CDAD cases remained relatively 
stable over time at ≈25%.
The numbers of adult hospital patients discharged with 
a CDAD diagnosis from 2000 through 2005 by age group 
are presented in the Table (6). The Figure illustrates the 
age-specifi c growth in CDAD incidence for the same pe-
riod. The rate of increase in the incidence of CDAD was 
steepest in the >85 age group, with the slope for the lin-
ear trend 11.3 (95% confi dence interval [CI] 7.6–14.9, p 
= 0.001), and ranged from 0.2 (95% CI 0.1–0.3, p<0.001) 
among the 18–44 age group to 4.8 (95% CI 3.2–6.0, 
p<0.001) among the 65–84 age group; the overall CDAD 
hospitalization incidence rose from 6.4 cases per 10,000 in 
2000 to 13.1 cases per 10,000 in 2005. When published 
population-based CDAD mortality estimates were applied 
to the annual CDAD hospitalization volumes, the crude 
case-fatality rate rose from 1.2% in 2000 to 2.3% in 2004; 
age-adjusting the 2004 estimate resulted in a similar case-
fatality rate of 2.2% (1).
Conclusions
In our analysis we detected a 23% annual increase in 
CDAD hospitalizations in the 6-year period from 2000 
through 2005. Moreover, the absolute number of CDAD 
hospitalizations more than doubled in all age groups except 
the youngest, for whom they increased by 74.1% over the 
study period. Additionally, we estimated that the age-ad-
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justed case-fatality rate for CDAD hospitalizations nearly 
doubled from 1.2% in 2000 to 2.2% in 2004.
Our numbers help put in perspective the observed 
increasing mortality rates related to CDAD in the United 
States. The recent report by Redelings et al. noted an in-
crease from 5.7 to 23.7 deaths with CDAD per million 
population from 1999 through 2004 in the United States, 
representing a 35% adjusted per annum increase (1). By 
observing a 23% per annum increase in the volume of 
hospitalizations with CDAD in the period 2000–2005, we 
demonstrate that at least half of the reported mortality in-
crease with CDAD is due to an increase in the incidence of 
hospitalizations with this severe infection. Increased hospi-
talization may in turn be related to a simple increase in the 
overall volume of CDAD or refl ect the increased virulence 
of the organism, leading to more cases of severe disease 
requiring hospitalization. We have also estimated that the 
unadjusted case-fatality rate did indeed increase from 1.2% 
in 2000 to 2.3% in 2004. While this doubling of deaths 
with CDAD is mirrored almost perfectly by the more-than 
doubling of CDAD admissions among all but the youngest 
age groups, who cumulatively represent 90% of all CDAD 
hospitalizations, age-adjusting the 2004 case-fatality esti-
mate did not change it substantially. This fi nding indirectly 
confi rms that the reported increase in CDAD deaths likely 
represents the effects of increased virulence of the organ-
ism (1,4).
Our analysis relied on ICD-9-CM coding to identify 
CDAD-related hospitalizations. Studies correlating the 
presence of the diagnostic code for CDAD to the presence 
of a laboratory confi rmation of the disease have not sug-
gested a clear over- or underdiagnosis trend in the admin-
istrative coding (2). However, the administrative nature of 
the data may have predisposed our case ascertainment to 
misclassifi cation. Giving credence to our numbers, how-
ever, is the report by McDonald et al., who noted near-
doubling of CDAD US hospital discharges, from 98,000 
in 1996 to 178,000 in 2003 (2). Additionally, while ex-
hibiting a similar absolute rise, CDAD primary diagnosis 
admissions as a fraction of all CDAD hospitalizations re-
mained constant. Although it is possible that the observed 
rise in CDAD hospitalizations is due to changes in coding 
practices, evidence of an increase in microbiologic detec-
tion of this pathogen argues against this explanation for 
our observations (8).
The incidence in adult CDAD-related hospitalizations 
increased substantially in the period 2000–2005. In view 
of the aging US population, this rapid pace of growth is 
alarming. If this rate of rise, along with the increase in 
virulence and diminished susceptibility to antimicrobial 
drug treatments, persists, CDAD will result not only in a 
considerable strain on the US healthcare system (9,10) but 
also in rising numbers of deaths related to this disease (1). 
Allocation of public health resources aimed at prevention 
of CDAD is necessary to mitigate this growing epidemic. 
Research into the best preventive strategies, such as limit-
ing the use of antimicrobial agents in both human disease 
and the food supply (11), is a public health imperative.
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Table. Absolute numbers of adult hospitalizations with Clostridium difficile, by age group, United States, 2000–2005 
Hospitalizations 2000 2001 2002 2003 2004 2005
18–44 y 14,738 15,001 18,747 19,393 22,168 25,662
45–64 y 28,280 29,527 39,421 43,290 50,898 61,757
65–84 y 69,018 74,010 98,148 105,404 122,875 147,675
>85 y 22,325 25,194 31,899 35,363 43,341 56,209
All adult 134,361 143,732 188,215 203,450 239,282 291,303
Figure. Changes in the age-specifi c Clostridium diffi cile–associated 
disease incidence rate per 10,000 population in the United States, 
2000–2005.
C. diffi cile–related Hospitalizations, United States
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